Literature DB >> 29045889

The Pathway to a Universal Influenza Vaccine.

Catharine I Paules1, Hilary D Marston1, Robert W Eisinger1, David Baltimore2, Anthony S Fauci3.   

Abstract

Development of a universal influenza vaccine is a research priority for the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health. To facilitate this goal, we convened a workshop in Rockville, Maryland to identify knowledge gaps in influenza research and develop strategies to fill them.
Copyright © 2017.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29045889     DOI： 10.1016/j.immuni.2017.09.007

Source DB:  PubMed          Journal:  Immunity        ISSN： 1074-7613            Impact factor:   31.745


  78 in total

1.  Hemagglutinin Stalk-Reactive Antibodies Interfere with Influenza Virus Neuraminidase Activity by Steric Hindrance.

Authors:  Yao-Qing Chen; Linda Yu-Ling Lan; Min Huang; Carole Henry; Patrick C Wilson
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

2.  Protection by universal influenza vaccine is mediated by memory CD4 T cells.

Authors:  Sophie A Valkenburg; Olive T W Li; Athena Li; Maireid Bull; Thomas A Waldmann; Liyanage P Perera; Malik Peiris; Leo L M Poon
Journal:  Vaccine       Date:  2018-06-07       Impact factor: 3.641

Review 3.  VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design.

Authors:  Fang Chen; Netanel Tzarum; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2019-03-16       Impact factor: 7.090

4.  Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain.

Authors:  Florian Krammer; Peter Palese
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

Review 5.  CD4 T cells in protection from influenza virus: Viral antigen specificity and functional potential.

Authors:  Andrea J Sant; Anthony T DiPiazza; Jennifer L Nayak; Ajitanuj Rattan; Katherine A Richards
Journal:  Immunol Rev       Date:  2018-07       Impact factor: 12.988

6.  A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.

Authors:  Emily J Erbelding; Diane J Post; Erik J Stemmy; Paul C Roberts; Alison Deckhut Augustine; Stacy Ferguson; Catharine I Paules; Barney S Graham; Anthony S Fauci
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

Review 7.  Distinct and complementary roles of CD4 T cells in protective immunity to influenza virus.

Authors:  Andrea J Sant; Katherine A Richards; Jennifer Nayak
Journal:  Curr Opin Immunol       Date:  2018-04-02       Impact factor: 7.486

8.  A Dose-finding Study of a Wild-type Influenza A(H3N2) Virus in a Healthy Volunteer Human Challenge Model.

Authors:  Alison Han; Lindsay M Czajkowski; Amanda Donaldson; Holly Ann Baus; Susan M Reed; Rani S Athota; Tyler Bristol; Luz Angela Rosas; Adriana Cervantes-Medina; Jeffery K Taubenberger; Matthew J Memoli
Journal:  Clin Infect Dis       Date:  2019-11-27       Impact factor: 9.079

9.  Crowd on a Chip: Label-Free Human Monoclonal Antibody Arrays for Serotyping Influenza.

Authors:  Hanyuan Zhang; Carole Henry; Christopher S Anderson; Aitor Nogales; Marta L DeDiego; Joseph Bucukovski; Luis Martinez-Sobrido; Patrick C Wilson; David J Topham; Benjamin L Miller
Journal:  Anal Chem       Date:  2018-07-20       Impact factor: 6.986

10.  Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface.

Authors:  Seth J Zost; Jinhui Dong; Iuliia M Gilchuk; Pavlo Gilchuk; Natalie J Thornburg; Sandhya Bangaru; Nurgun Kose; Jessica A Finn; Robin Bombardi; Cinque Soto; Elaine C Chen; Rachel S Nargi; Rachel E Sutton; Ryan P Irving; Naveenchandra Suryadevara; Jonna B Westover; Robert H Carnahan; Hannah L Turner; Sheng Li; Andrew B Ward; James E Crowe
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.